Stay updated with breaking news from Ablative Solutions Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal...
This phase 2 randomized trial examines the antihypertensive efficacy and safety of different zilebesiran dosing regimens.
/PRNewswire/ -- The "Renal Denervation Technologies - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global...
April 12, 2023—Ablative Solutions, Inc. announced the completion of patient enrollment in the TARGET BP I study, which is evaluating alcohol-med
The global renal denervation market size was valued at $156,327.4 thousand in 2020, and is projected to reach $4,555,983.0 thousand by 2030.